Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Quick Explanation



    Arthur L. Reingold is a world-class infectious disease epidemiologist (h-index 102–104; ~41,000–46,700 citations) whose career spans landmark outbreak investigations and population-based vaccine surveillance, including the landmark 2003 NEJM report of declining invasive pneumococcal disease after conjugate vaccine introduction . His work is rigorously designed and transparently limited, though much of it is collaborative consortium science where individual attribution is difficult.


     Long Explanation



    A Career Built on Population-Based Infectious Disease Epidemiology

    Arthur L. Reingold's record shows rare breadth and durability across four decades of field epidemiology. He was first author of the 1982 Lancet paper defining nonmenstrual toxic shock syndrome during the original TSS investigations , and senior author of the 1985 NEJM investigation that identified pasteurized milk as the vehicle in a Massachusetts listeriosis outbreak (49 patients, 29% mortality) . His later surveillance work quantified the population-level impact of conjugate vaccines: the 2003 NEJM PCV7 study (2,397 citations) , the 2011 NEJM decade-update on bacterial meningitis (1,081 citations) , and influential ACIP hepatitis B recommendations .

    Rigor in the Supplied Primary Study: MenACWY-D Effectiveness

    The supplied full-text record illustrates his methodological standard. In a population- and laboratory-based case-control study (181 adolescent cases, 199 friend/school controls, ABCs/MeningNet sites, 2006-2013), one dose of MenACWY-D was 69% effective overall (95% CI 51-80%), with effectiveness waning from 79% at <1 year to 61% at 3-<8 years; serogroup C VE was 77% but serogroup Y VE only 51% (95% CI 1-76%), and serogroup W VE could not be calculated due to sparse cases. The team used GEE models adjusting for underlying conditions and smoking, verified vaccination records, and ran conditional logistic regression as a sensitivity analysis, concluding a booster was warranted . This directly informed ACIP policy and demonstrates honest reporting of null-adjacent and imprecise strata (serogroup Y CI reaching 1%), a marker of low selective-reporting risk.

    Critical Appraisal: Strengths, Blindspots, and Caveats

    Strengths. Reingold's metrics are elite: h-index 102 with 40,976 citations over 365 papers (one record) and h-index 104 with 46,697 citations over ~400 works (OpenAlex), with sustained citation rates exceeding 1,500/year through 2026. His signature contribution is methodological: extracting valid effectiveness and etiologic signals from imperfect, low-incidence surveillance data using population-based active surveillance, case-control designs, and explicit bias analysis.

    Blindspots and caveats. Most highly cited works place him as a middle author on large CDC/Emerging Infections Program consortia, so his individual intellectual contribution is hard to isolate from the surveillance infrastructure and CDC coauthors. Funding came through CDC cooperative agreements , and his long ACIP workgroup service aligns his output with institutional immunization policy consensus, which readers should weigh when interpreting uniformly favorable vaccine-effectiveness conclusions. Key uncertainties in the reviewed study itself: overlapping CIs across time strata mean the waning trend is suggestive rather than statistically definitive; no serogroup A cases occurred, so serogroup A VE is unknown; and friend/school control matching may introduce enrollment bias. These caveats are appropriately disclosed by the authors rather than hidden, which is itself evidence of scientific integrity.

    What would change this assessment: independent replications finding substantially lower or non-waning MenACWY-D effectiveness, evidence of selective authorship credit, or unreproduced surveillance findings would lower the score. None is present in the supplied record. Confidence: high on bibliometrics and the primary study (sourced full text); moderate on attributing consortium papers' methods specifically to Reingold.



    Feedback:    

    Updated: November 17, 2026

     BGPT Author Review



    Scientific Quality

    90%

    H-index 102-104 with ~41,000-46,700 citations across 365-400 works places Reingold in the top tier of infectious disease epidemiologists globally. First-authorship on defining TSS and listeriosis investigations and co-authorship on multiple NEJM landmark surveillance studies demonstrate sustained, reproducible scientific contribution over 45 years. Deduction from 10: much of his most-cited work is consortium science where individual methodological credit is diffuse, and his record shows no major methodological innovation in analytic epidemiology itself.



    Communication Quality

    80%

    His papers, exemplified by the supplied Pediatrics study, report methods, limitations, and policy implications clearly and quantitatively, making dense surveillance findings accessible to clinicians and policymakers. Deduction: much of his output is consortium-authored MMWR/ACIP-style writing that is deliberately standardized rather than individually distinctive or broadly accessible to lay readers.



    Author Novelty

    60%

    His novelty lies in being first to define and quantify problems (nonmenstrual TSS, milk-borne listeriosis, PCV herd effects, MenACWY-D waning) rather than in inventing new methods or theories. Applied discovery epidemiology of this kind is highly valuable but incremental relative to paradigm-shifting work; later papers largely extend established surveillance templates.



    Scientific Rigor

    90%

    The supplied study exemplifies rigor: population- and laboratory-based case ascertainment, verified vaccination records, adjustment for confounders, dual analytic approaches (GEE plus conditional logistic regression), and explicit disclosure of overlapping CIs, unestimable strata, and enrollment-bias concerns. Deduction: low-incidence designs inherently limit power, and some imprecise strata (serogroup Y CI 1-76%) approach uninformative bounds despite transparent reporting.

     Hypothesis Graveyard



    That the observed VE waning proves serogroup replacement or bacterial escape: not supported, since the study found no serogroup shift among cases and waning was consistent across vaccine serogroups with stable surveillance methods.


    That single-dose MenACWY-D is ineffective: contradicted by the overall 69% effectiveness (CI excluding 50%) and 77% effectiveness against serogroup C within the first years.

     Science Art


    Author Review: Arthur Reingold Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT